AT-527

A leader in the discovery of oral direct-acting antiviral therapies.

Atea’s most advanced antiviral drug candidate, AT-527, is being evaluated in a multi-national multi-center Phase 2 clinical trial for the treatment of patients with moderate COVID-19 and risk factors for poor outcomes. As an orally-administered direct-acting antiviral, AT-527 is designed to arrest the progression of COVID-19 by inhibiting replication of the SARS CoV-2 virus.

Learn More

ATEA PHARMACEUTICALS

Innovative discovery and efficient development of potentially transformative therapies for patients with life-threatening viral diseases.

Atea is a clinical stage biopharmaceutical company working to address unmet medical needs with innovative oral antiviral therapies.

OUR SCIENCE

The power of our purine nucleotide prodrug platform.

Leveraging our platform, we have discovered and are rapidly advancing novel oral direct-acting antiviral drug candidates. Utilizing unique chemical modifications, these product candidates are designed to have the potential for enhanced antiviral activity and selectivity.

A network of hubs and spokes is suspended, representing the idea of a modular platform.

COVID-19 AND AT-527

AT-527 addresses the key challenges of the COVID-19 pandemic and beyond.

For the treatment of COVID-19, we need transformational solutions, and we believe that oral, safe, direct-acting antivirals can play an essential role worldwide. The value and global health impact of a direct-acting antiviral is to rapidly inhibit viral replication in the early phase of infection, which has the effect of reducing disease progression and curtailing the spread of infection.

While vaccines will play an important role in mitigating the COVID-19 pandemic, we will need treatment options to stay ahead of the virus. To treat patients who are waiting to or do not want to be immunized and for patients for whom the vaccine does not create protective immunity, direct-acting antivirals are and will remain an essential complement to vaccines.

AT-527 is an oral, direct-acting antiviral drug candidate.

AT-527 is designed for easy and early administration to reduce burden and duration of disease. AT-527 has the potential to be used for pre- and post-exposure prophylaxis, to reduce transmission and to impact long-term COVID sequelae.

Similar to Tamiflu®

Complementary medical intervention to vaccination similar to the influenza paradigm (Tamiflu®)

Significant advantages vs antibodies

Significant advantages vs antibodies:

  • convenient for patients and healthcare workers
  • global reach
  • manufacture
  • scale-up
  • cost
Effective vs. mutations

Highly-conserved target should enable antiviral activity in the presence of multiple mutations

anticipated to be effective again st future coronaviruses

Antiviral activity against potential future coronaviruses beyond SARS-CoV-2 anticipated

NEWS

Follow our progress.

See updates on AT-527, other Atea product candidates and company news.

Atea Pharmaceuticals Reports Full Year 2020 Financial Results and Provides Corporate Update

– Rapid advancement of AT-527 for COVID-19 – – Strategic collaboration with Roche to develop and commercialize AT-527 for COVID-19 – – Initiation of Phase 1a trial of AT-752 for dengue fever – – Crossover financing and IPO – BOSTON, March 30, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call on March 30, 2021

BOSTON, March 23, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that it will host a live conference call and audio webcast on Tuesday, March 30, 2021 at 4:30 p.m.

Atea Pharmaceuticals Presents Favorable Phase 1 Results for AT-527 at 28th Annual Conference on Retroviruses and Opportunistic Infections

High Lung Levels of Active Triphosphate Predicted with Oral AT-527 for COVID-19 Patients Data Supportive of AT-527 550 mg BID Dosing Regimen BOSTON, March 06, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today presented